全文获取类型
收费全文 | 86978篇 |
免费 | 7056篇 |
国内免费 | 876篇 |
专业分类
耳鼻咽喉 | 542篇 |
儿科学 | 1829篇 |
妇产科学 | 2287篇 |
基础医学 | 9511篇 |
口腔科学 | 1588篇 |
临床医学 | 6341篇 |
内科学 | 11134篇 |
皮肤病学 | 1286篇 |
神经病学 | 2631篇 |
特种医学 | 4704篇 |
外国民族医学 | 26篇 |
外科学 | 10741篇 |
综合类 | 1823篇 |
现状与发展 | 10篇 |
预防医学 | 3471篇 |
眼科学 | 556篇 |
药学 | 3261篇 |
9篇 | |
中国医学 | 300篇 |
肿瘤学 | 32860篇 |
出版年
2024年 | 116篇 |
2023年 | 4132篇 |
2022年 | 5878篇 |
2021年 | 6273篇 |
2020年 | 6664篇 |
2019年 | 4407篇 |
2018年 | 4163篇 |
2017年 | 4097篇 |
2016年 | 4069篇 |
2015年 | 4335篇 |
2014年 | 7567篇 |
2013年 | 5699篇 |
2012年 | 3970篇 |
2011年 | 3248篇 |
2010年 | 4613篇 |
2009年 | 4208篇 |
2008年 | 2072篇 |
2007年 | 2100篇 |
2006年 | 1704篇 |
2005年 | 1473篇 |
2004年 | 1117篇 |
2003年 | 1103篇 |
2002年 | 1169篇 |
2001年 | 1189篇 |
2000年 | 928篇 |
1999年 | 1021篇 |
1998年 | 933篇 |
1997年 | 698篇 |
1996年 | 681篇 |
1995年 | 630篇 |
1994年 | 464篇 |
1993年 | 387篇 |
1992年 | 315篇 |
1991年 | 337篇 |
1990年 | 330篇 |
1989年 | 379篇 |
1988年 | 400篇 |
1987年 | 325篇 |
1986年 | 105篇 |
1985年 | 174篇 |
1984年 | 165篇 |
1983年 | 149篇 |
1982年 | 172篇 |
1981年 | 155篇 |
1980年 | 137篇 |
1979年 | 106篇 |
1978年 | 78篇 |
1977年 | 65篇 |
1976年 | 76篇 |
1975年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
《Journal of thoracic oncology》2020,15(4):618-627
IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. 相似文献
73.
《European urology》2020,77(1):e21-e22
74.
75.
随着临床诊治水平的不断进步,肝细胞性肝癌(hepatocellular carcinoma,HCC)患者的总生存时间获得延长,但是HCC骨转移发生率则显著升高,HCC骨转移的筛查与诊治已成为全球性热点与难点问题。明确HCC骨转移的致病机制有助于临床肿瘤筛查及诊疗手段的提高,血管形成和上皮-间质转化(epithelial mesenchymal transition,EMT)是HCC骨转移的主要致病机制,骨微环境使得HCC骨转移持续发生。明确HCC骨转移的预后因素有利于对此类患者进行早期干预以延长患者总生存期,但目前尚未就HCC骨转移患者的治疗策略达成共识。本文就HCC骨转移分子病理学致病机制的研究进展进行综述,为早期筛查、精准诊断和个体化治疗提供依据。 相似文献
76.
77.
78.
《The journal of sexual medicine》2015,12(12):2303-2312
IntroductionVascular age, as derived from the SCORE project algorithm for cardiovascular (CV) risk estimation, is an effective way for communicating CV risk. However, studies on its clinical correlates are scanty.AimTo evaluate if the difference between vascular and chronological age (Δage), in a population of subjects with erectile dysfunction (ED), can identify men with a worse risk profile.MethodsA consecutive series of 2,853 male patients attending the outpatient clinic for erectile dysfunction (ED) for the first time was retrospectively studied. Among them, 85.4% (n = 2,437) were free of previous MACE and were analyzed.Main Outcome MeasuresSeveral clinical, biochemical, and penile color Doppler parameters were studied. Vascular age was derived from the SCORE project algorithm, and the Δage was considered.ResultsHigher Δage is associated with several conventional (family history of CV diseases, hyperglycemia, elevated triglycerides, and increased prevalence of metabolic syndrome) and unconventional (severity of ED, frequency of sexual activity, alcohol abuse, lower education level, fatherhood, extramarital affairs, compensated hypogonadism, and low prolactin levels) risk factors. Δage is inversely related to penile color Doppler parameters, including flaccid and dynamic peak systolic velocity and flaccid acceleration (β = −0.125, −0.113, and −0.134, respectively, all P < 0.0001).ConclusionsIn subjects referring for ED without a personal history of CV events, Δage is associated with an adverse cardio-metabolic profile and worse penile color Doppler ultrasound parameters. Δage provides a simple method for identifying high-risk men that must undergo significant modification in their lifestyle and risk factors. In addition, it can be considered a simple, inexpensive, and safe surrogate marker of penile arterial damage. 相似文献
79.
80.